Latest news with #Schott
CNBC
4 days ago
- Business
- CNBC
JPMorgan's top biotech and pharma picks for the second half
Biopharmaceutical stocks' underperformance versus the broader market for a third-straight year is an opportunity for investors, according to JPMorgan. Analyst Chris Schott said in the firm's June outlook for biopharma that the sector's poor performance can be traced back to concerns over President Donald Trump's tariffs and his " most favored nation " executive order. The SPDR S & P Biotech ETF (XBI) has pulled back about 7% so far in 2025, while the S & P 500 has notched a nearly 2% gain. The stock action is overdone, according to Schott, as he expects any impact from this policy will be "manageable." Valuations are historically depressed, Schott said, which means the sector has already priced in the the worst possible outcome. "The sector [should be] able to largely mitigate the impact of tariffs in the mid/long term through manufacturing repatriation and 2) [there's] no clear path for MFN ["most favored nation"] to move forward without Congressional approval (outside of IRA price negotiations)," Schott said. Fundamentals for biopharma stocks have improved in recent years, which should support "a more manageable sales/EPS erosion outlook for most names," he added. Here's a look at some of JPMorgan's favorite biotech and pharma stocks heading into the second half of the year. All stocks on the list are rated overweight by the firm. Eli Lilly stock is among JPMorgan's top picks among the group. Shares are about flat in 2025, and have slipped roughly 8% over the past 12 months. The company agreed to purchase SiteOne Therapeutics in a roughly $1 billion deal last week , which could allow Lilly to develop non-opioid treatments for chronic pain conditions. LLY YTD mountain Eli Lilly stock in 2025. Developing non-opioid pain drugs is a key focus for the industry, with Vertex Pharmaceuticals recently approving its Journavx Nav1.8 inhibitor. About 84% of analysts polled by FactSet maintain a buy rating on Eli Lilly stock, with their consensus price target equating to nearly 29% upside. Gilead Sciences is also one of JPMorgan's top picks. Shares have soared more than 20% so far in 2025. GILD YTD mountain Gilead Sciences stock in 2025. Analysts surveyed by FactSet think the stock has more room to run after a strong first half of the year. Alongside a consensus buy rating, the average analyst price target calls for more than 5% upside. The company recently announced key phase three trial data tied to its Trodelvy cancer treatment that showed the drug lowered the risk of a severe form of breast cancer when used in combination with Merck 's Keytruda immunotherapy treatment. Other names on the list include Regeneron Pharmaceuticals and Bristol Myers Squibb .
Associated Press
6 days ago
- Business
- Associated Press
Cardinal Health launches new medical device for the continuous monitoring of three essential vital signs in one system
Kendall DL™ Multi System simplifies patient monitoring, drives efficiencies for providers DUBLIN, Ohio, June 4, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today the U.S. launch of its multi-parameter, single-patient use monitoring cable and lead wire system that enables the continuous monitoring of cardiac activity, blood oxygen level and temperature with one point of connection. The new Kendall DL™ Multi System is designed to travel with the patient from admission to discharge for smooth transport. It helps improve clinician workflows, provides reliable monitoring to help determine the best course of care, and maximizes value across the hospital. 'This innovative addition to the Kendall DL portfolio removes complexity for busy care teams, and at the same time, helps enhance clinical performance with multi-parameter monitoring,' said Rachel Schott, global vice president for specialty products at Cardinal Health. 'The product streamlines steps that clinicians must follow to provide effective care and controls common lead wire clutter with its built-in cable management system.' The Kendall DL™ Multi System offers a proprietary design that features clinically proven technology to reduce the incidence of false 'leads off' alarms2 (i.e., indications that wires connected to the patient's body are not properly connected), as well as motion-related artifacts in electrocardiogram (ECG) tracings,† which are recorded disturbances due to a patient's movement. This yields cleaner ECG tracings and allows clinicians to more effectively prioritize the care they need to administer. As a single-patient use product, the system helps reduce cross contamination related to reusable lead wires for the monitoring of cardiac activity, blood oxygen level and temperature.1 This helps lower the chance of infection and the need for additional hospital days or readmissions.3 The system is eligible for medical device reprocessing through Cardinal Health. 'By enabling more efficient workflows and driving clinical excellence, this new solution can potentially support the financial performance of healthcare providers,' Schott said. 'Expanding our Kendall DL offerings demonstrates our commitment to providing products designed to address multiple clinical and operational challenges across healthcare organizations, and builds upon our legacy of safe, high-quality patient monitoring solutions providers have come to trust.' The Kendall DL™ Multi System is now available for health systems in the U.S. For more information, please visit us here. About Cardinal Health Cardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of nuclear pharmacies and manufacturing facilities; and a provider of performance and data solutions. Our company's customer-centric focus drives continuous improvement and leads to innovative solutions that improve people's lives every day. Learn more about Cardinal Health at and in our Newsroom. Contacts References: †Cardinal Health Data on File – OEM Grabber Comparisons Report, Dec 2024 1. Brown DQ. Disposable vs reusable electrocardiography leads in development of and cross contamination by resistant bacteria. Crit Care Nurse. 2011 Jun;31(3):62 8. doi: 10.4037/ccn2011874. PMID: 21632593. 2. Albert N, Murray T, Bena J, et al. Differences in alarm events between disposable and reusable electrocardiography lead wires. Am J Crit Care. 2015 Jan;24(1):67-73; quiz 74. doi: 10.4031/ajcc2015663. 3. Saunders R, Hansson Hedblom A. The economic implications of introducing single patient ECG systems for cardiac surgery in Australia. Clinicoecon Outcomes Res. 2021 Aug 13;13:727-735. doi: 10.2147/CEOR.S232527 View original content to download multimedia: SOURCE Cardinal Health
Mint
26-05-2025
- Business
- Mint
The SC's Schott Glass verdict struck bullseye in favour of policy certainty
There's a temptation that afflicts every regulator over time: the urge to intervene. Like the man with a hammer who sees everything as a nail, some regulators across the globe begin to see their relevance lying in their reach, not their restraint. They start mistaking regulation for virtue and enforcement for wisdom. Markets, in their view, are suspect until proven innocent. India, which aims to be a global hub for manufacturing and innovation, can ill afford such regulatory excess. When enforcement diverges from economic logic, when success itself is treated as suspicious, we risk turning the very institutions meant to foster growth into instruments that stifle it. Also Read: Competition: We must raise the CCI's tooth-to-tail ratio This is the context in which the Supreme Court's (SC) recent judgment in Competition Commission of India vs Schott Glass India Pvt Ltd must be seen. Fortunately, it is a principled reaffirmation of how regulation must serve economic freedom, not strangle it. For over 15 years, Schott Glass India faced allegations of abusing its market position. Its rival, Kapoor Glass, accused it of exclusionary discounts, discriminatory terms and selective supply refusals. The Competition Commission of India (CCI) agreed, imposed a hefty fine and issued a cease-and-desist order. But what the SC found after a forensic examination of the case was telling: the CCI's conclusions were not built on proof, but on presumption. The regulator had relied on untested statements, outdated correspondence and a startling absence of economic harm analysis. It had denied Schott a chance to cross-examine adverse witnesses and failed to assess whether consumers or competitors were actually harmed. Also Read: How the CCI has erred in punishing Make My Trip-Goibibo and OYO The SC ruling exposed a deeper institutional failing—a regulatory tendency to punish dominance without proving abuse, treat scale as suspicious and bypass due process in pursuit of outcomes. In doing so, the SC gave India's regulation of competition doctrinal clarity. For the first time, it categorically affirmed that Section 4 of the Competition Act must be interpreted through an 'effects-based" lens. In plain terms, it's not enough to show that a firm is dominant or aggressive; regulators must prove that its conduct harms the competitive process by limiting choice, raising prices or deterring market entry. The goal of an antitrust law is not to humble the successful, but ensure conditions under which others can succeed too. Dominance is not illegal. It becomes problematic only when it is abused to block rivals unfairly or harm consumers. Schott, the SC noted, did neither. No converter exited the market. Prices were stable. Imports actually rose. Schott's volume-based rebates were tied solely to the quantity purchased and applied uniformly across buyers. Such scale-based discounts, the SC noted, are not only economically rational, but also enhance efficiency, letting firms transmit savings downstream and reduce prices for consumers. The rival alleging harm, Kapoor Glass, offered no credible proof of exclusion. Also Read: India is becoming a complex battleground: Marico CEO on rising FMCG competition In today's world, where global capital is cautious and geopolitical conditions are shifting, India's credibility as an investment destination rests on the predictability and fairness of its regulatory institutions. This judgment, unlike some others, strengthens that credibility. It also indicates a need for systemic reform, which must come from within regulatory bodies. The CCI must invest in better economic expertise, adopt a more rigorous evidentiary framework and ensure procedural fairness not as an afterthought, but as a foundational principle. There will be four implications of Schott judgment. First, it settles that abuse of dominance under India's competition law requires proof of actual harm, not just of large operational scale or market share. While the ruling endorses an effects-based standard, it stops short of laying out a clear framework (rightly so). Still, with this principle affirmed, the CCI can use it for a clear framework. Second, regulators must improve procedural rigour. The judgment rebukes the CCI for denying cross-examination and relying on biased untested testimony. Natural justice is a non-negotiable part of competition inquiries. Third, investor confidence gets a boost: The verdict sends a reassuring message to global and domestic investors that success will not be prosecuted and India protects lawful enterprise. Fourth, weaponization of competition law has been curtailed to an extent. The decision sets a precedent that commercial grievances cannot masquerade as competition complaints. This will likely reduce frivolous or malicious filings aimed at competitors. Also Read: Competition penalties going by global turnover call for a rethink Importantly, the Schott verdict restores predictability of case outcomes. In a world where capital moves at the speed of doubt, businesses don't fear regulation, but arbitrariness. India's ease of doing business will not be built on slogans or rankings, but on a steady assurance of policy certainty, where the rules are clear, enforcement is fair and success is not punished for its own sake. But for this to endure, India must not stand in the way of businesses seeking scale. We cannot build a $5 trillion economy while treating scale with suspicion. Large firms are not the enemy of competition; they are often its most visible outcome. To demonize them is to punish success and reward mediocrity. The SC has rightly drawn the line between market dominance and abuse. But this line must be guarded in every future ruling, not just honoured in this one. These are the authors' personal views. The authors are, respectively, a public policy professional, and assistant professor of economics at the Faculty of Management Studies, University of Delhi.
Fashion United
14-05-2025
- Business
- Fashion United
Etam: employees rally against site closure threatening 55 jobs
Approximately 30 employees from a subsidiary of the Etam group, travelling by bus from the north, protested on Tuesday in front of the lingerie brand's headquarters in Clichy (Hauts-de-Seine) against the closure of their site, which threatened 55 jobs. Beneath the windows of the Etam group's headquarters (Etam, Undiz, Maison 123, Livy, Ysé), the demonstrators unfurled banners with textile-themed slogans: 'We cut patterns, not staff', 'Sacking us is cheeky' and 'Etam strips us bare'. Dressed in underwear and swimwear worn proudly over their clothes, around 30 employees from the 'Tech Center', a design office based in Marcq-en-Baroeul, on the outskirts of Lille, travelled by bus to protest against the closure of this Etam group subsidiary, which was announced on March 18 and threatened 55 jobs. 'It's an entire French skill set that's being shut down,' lamented Claudine Coppens, a 51-year-old pattern maker at the northern innovation site. Florence Manceau, a pattern maker, joined Etam in 1996, left the company for a while, before being called back in March 2024 'to work at the Tech Center'. 'They hired six new people last year, yet ultimately, they're implementing a redundancy plan. We don't understand,' she told AFP, also noting 'derisory (...) redeployment amounts'. 'The group has clearly made a difficult decision, but one that is necessary for the future of its business,' commented Marie Schott, chief executive officer of the Etam brand and president of the Tech Center. She asserted that she understood the 'anger' expressed and hoped to 'find a favourable outcome that can satisfy everyone'. When questioned by AFP, she cited a 'tightening of market conditions' in the clothing and lingerie sector, with 'inflation and a fall in household purchasing power, which has led to an overall slowdown in sales' in the sector. The design office, which opened in 2017, handled sampling and pattern making, 'an activity that now accounts for only 2 percent of Etam's products', explained Schott, with the remainder being purchased as 'finished products'. 'It's a massacre, many textile companies are collapsing. The trades are dead, it's cheaper in Asia,' lamented Elsa Lehman, 28, who has been with Etam for three years, from the demonstration in Clichy. The deadline for submitting the redundancy plan is set for May 19. The Etam group has 5,700 employees worldwide, including 3,930 in France, according to Schott. This article was translated to English using an AI tool. FashionUnited uses AI language tools to speed up translating (news) articles and proofread the translations to improve the end result. This saves our human journalists time they can spend doing research and writing original articles. Articles translated with the help of AI are checked and edited by a human desk editor prior to going online. If you have questions or comments about this process email us at info@
Yahoo
13-05-2025
- Business
- Yahoo
Why Teva Pharmaceuticals Stock Blasted 6% Higher Today
A recommendation upgrade from a veteran investment bank put some real zip in the shares. The analyst behind the change is now bullish on Teva's future. 10 stocks we like better than Teva Pharmaceutical Industries › A positive change in recommendation from a well-known bank was the fuel propelling Teva Pharmaceutical Industries's (NYSE: TEVA) well higher on Monday. The company, known for being a top producer of generic drugs, saw its share price swell almost 6% as a result. That was good enough to beat even the very frothy S&P 500's (SNPINDEX: ^GSPC) 3.3% gain that trading session. The person behind the modification was JPMorgan Chase analyst Chris Schott, who pushed up his Teva stock recommendation one notch from neutral to overweight (read: buy). He also bumped his price target higher, from $21 per share to $23. The new level anticipates upside of 28% on the most recent closing stock price. According to reports, much of Schott's new analysis of Teva centers on the cost-cutting measures the company announced recently. In his opinion, the $700 million initiative makes management's goal of reaching a 30% operating margin by 2027 achievable. At the same time, it should also provide sufficient room for the company to keep its pipeline programs funded. Past that year, the prognosticator is bullish on Teva's branded products. In his estimation, drugs like Austedo, Olanzapine, and Duvakitug could drive the company's growth well higher. For the most part, the clutch of analysts tracking Teva are also expecting improvement in key fundamentals. Collectively, they feel full-year 2025 revenue will tick up by almost 3% this year over 2024 to $17 billion, with per-share net income improving at just under 2%. And although 2026 revenue is forecast to creep less than 1% higher year over year, that per-share net income figure should rise by a robust 9%. To me, Teva has quite a strong position as a crucial manufacturer of generic drugs. Yet it certainly isn't neglecting the branded side of its business, which is showing promise these days. I also like how management has assertively cleaned the balance sheet. Therefore, I don't blame Schott for being more bullish on Teva's future. Before you buy stock in Teva Pharmaceutical Industries, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Teva Pharmaceutical Industries wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $614,911!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $714,958!* Now, it's worth noting Stock Advisor's total average return is 907% — a market-crushing outperformance compared to 163% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 12, 2025 JPMorgan Chase is an advertising partner of Motley Fool Money. Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends JPMorgan Chase. The Motley Fool has a disclosure policy. Why Teva Pharmaceuticals Stock Blasted 6% Higher Today was originally published by The Motley Fool
